Zevra Therapeutics (NASDAQ:ZVRA) Stock Falls 5.1% on Insider Selling

Posted by Geri Gentry on Oct 15th, 2026

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) were down 5.1% during trading on Tuesday after an insider sold shares in the company. The company traded as low as $10.79 and last traded at $10.7450. 128,543 shares changed hands during trading, a decline of 90% from the average daily volume of 1,252,757 shares. The stock had previously closed at $11.32.

Specifically, CEO Neil McFarlane sold 20,000 shares of Zevra Therapeutics stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $11.25, for a total transaction of $225,000.00. Following the completion of the transaction, the chief executive officer directly owned 417,225 shares of the company’s stock, valued at $4,693,781.25. The trade was a 4.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ZVRA. Canaccord Genuity Group lowered their price target on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating on the stock in a report on Monday, July 27th. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a report on Thursday, August 6th. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. BTIG Research decreased their price objective on shares of Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating for the company in a research report on Monday, July 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $26.00 price objective on shares of Zevra Therapeutics in a research report on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $27.14.

Check Out Our Latest Stock Analysis on Zevra Therapeutics

Zevra Therapeutics Price Performance

The firm has a fifty day simple moving average of $11.53 and a 200 day simple moving average of $11.41. The company has a market capitalization of $607.46 million, a price-to-earnings ratio of 6.58 and a beta of 0.98.

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.14. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. The business had revenue of $39.66 million during the quarter, compared to the consensus estimate of $33.88 million. Research analysts predict that Zevra Therapeutics, Inc. will post 0.72 EPS for the current year.

Institutional Investors Weigh In On Zevra Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZVRA. Tidal Investments LLC acquired a new position in shares of Zevra Therapeutics during the 2nd quarter worth about $150,000. WINTON GROUP Ltd lifted its stake in Zevra Therapeutics by 49.0% in the 2nd quarter. WINTON GROUP Ltd now owns 24,335 shares of the company’s stock valued at $349,000 after buying an additional 8,001 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in Zevra Therapeutics in the 2nd quarter valued at about $28,000. Wellington Management Group LLP boosted its holdings in Zevra Therapeutics by 5.2% in the 2nd quarter. Wellington Management Group LLP now owns 164,538 shares of the company’s stock worth $2,359,000 after buying an additional 8,121 shares during the last quarter. Finally, Globeflex Capital L P acquired a new stake in Zevra Therapeutics in the 2nd quarter worth about $2,752,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

(Get Free Report)

Zevra Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines.

Zevra’s lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat.